62 related articles for article (PubMed ID: 36439109)
1. Machine-learning prediction of a novel diagnostic model using mitochondria-related genes for patients with bladder cancer.
Li J; Wang Z; Wang T
Sci Rep; 2024 Apr; 14(1):9282. PubMed ID: 38654047
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Community series in unveiling the tumor microenvironment by machine learning to develop new immunotherapeutic strategies, volume II.
Zheng P; Liu J
Front Immunol; 2024; 15():1351597. PubMed ID: 38327521
[No Abstract] [Full Text] [Related]
3. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
4. Unveiling the interplay between mutational signatures and tumor microenvironment: a pan-cancer analysis.
Luo LZ; Li S; Wei C; Ma J; Qian LM; Chen YX; Wang SX; Zhao Q
Front Immunol; 2023; 14():1186357. PubMed ID: 37283742
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma.
Yang J; Xiang T; Zhu S; Lao Y; Wang Y; Liu T; Li K; Ma Y; Zhong C; Zhang S; Tan W; Lin D; Wu C
Int J Biol Sci; 2023; 19(8):2551-2571. PubMed ID: 37215984
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential.
Butler K; Banday AR
J Hematol Oncol; 2023 Mar; 16(1):31. PubMed ID: 36978147
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
8. Integrated Analysis Revealed an Inflammatory Cancer-Associated Fibroblast-Based Subtypes with Promising Implications in Predicting the Prognosis and Immunotherapeutic Response of Bladder Cancer Patients.
Chen H; Yang W; Xue X; Li Y; Jin Z; Ji Z
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555612
[TBL] [Abstract][Full Text] [Related]
9. Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature.
Qi D; Lu Y; Qu H; Dong Y; Jin Q; Sun M; Li Y; Quan C
iScience; 2024 Mar; 27(3):109138. PubMed ID: 38380255
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
Peng M; Chu X; Peng Y; Li D; Zhang Z; Wang W; Zhou X; Xiao D; Yang X
MedComm (2020); 2023 Dec; 4(6):e455. PubMed ID: 38107059
[TBL] [Abstract][Full Text] [Related]
11. Identification of bladder cancer subtypes and predictive model for prognosis, immune features, and immunotherapy based on neutrophil extracellular trap-related genes.
Guo C; Li P; Guo X; Wang X; Liu B; Cui L
Sci Rep; 2023 Nov; 13(1):20791. PubMed ID: 38012244
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of TROAP with molecular features, carcinogenesis, and related immune and pharmacogenomic characteristics in soft tissue sarcoma.
Tu C; Liu B; Li C; Feng C; Wang H; Zhang H; He S; Li Z
MedComm (2020); 2023 Oct; 4(5):e369. PubMed ID: 37731946
[TBL] [Abstract][Full Text] [Related]
13. Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer.
Yuan P; Li S; Xiong S; Zheng F; Yang L; Jiang M; Liu J; Liu X; Deng J; Zeng J; Fu B
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12489-12505. PubMed ID: 37450031
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of novel biomarkers affecting bladder cancer immunotherapy
Wang J; He X; Bai Y; Du G; Cai M
Front Immunol; 2022; 13():1051063. PubMed ID: 36439109
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
16. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
[TBL] [Abstract][Full Text] [Related]
18. A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting.
Sharifi L; Nowroozi MR; Amini E; Arami MK; Ayati M; Mohsenzadegan M
Int Immunopharmacol; 2019 Nov; 76():105880. PubMed ID: 31522016
[TBL] [Abstract][Full Text] [Related]
19. Macrophage immunotherapy: overcoming impediments to realize promise.
Sly LM; McKay DM
Trends Immunol; 2022 Dec; 43(12):959-968. PubMed ID: 36441083
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
